Among The Therapeutic Areas Of Partnering Interestfor The Top Pharmaceutical Companiesoncologyinflammation And Cns Are The Highest Rankedthe Market Value For These Indications Exceeds Any Calculation And Many Approaches Are Being Developed To Gain A Small Percentage Of Such Valueunfortunately Straight Forward Approaches To Target Proteins Driving Cancer Or Inflammatory Diseases Are Not Always Feasible Important Protein Targets In Theses Diseases Are Undrugable Through Their Active Siteoften Due To Off Target Effectsindeeddrugs That Bind To The Active Site Of Target Proteins Might Mimic The Structure Of Energy Substrates Aefor Example When The Protein S Active Site Harbors Systemic Energy Substrates Such As Atp And Gtpaccordinglysuch Drugs Might Switch Off Other Proteins That Are Important For The Activity Of Specific Cells In The Body By Contrastallosteric Sites Are Highly Specific To A Given Protein Target And In Factnature Employs These Sites To Selectively Modulate Given Proteinsallinky Has Developed Its Own Proprietary Technology Platform To Identify Allosteric Sites In Protein Targetsand To Thereafter Develop Allosteric Compoundssmall Moleculeswith Therapeutic Propertiesindeedsome Top Selling Drugs In The Market Are Allosteric Compounds Allinky Is Currently Advancing Drug Development Programs Focused On Two Families Ofinnovative Proprietary Small Moleculesallosteric Inhibitors Aik3 And Aik4These Therapeutic Molecules Are Being Developed To Treat Inflammatory Diseases Like Copdchronic Obstructive Pulmonary Diseaseand Amdage Related Macular Degenerationas Well As Cancer Driven By The Ras Family Of Proto Oncogenes That Are Found In Certain Types Of Lungcolorectal And Pancreatic Cancer As Well As Lymphomas
